Beyond antibodies: ankyrins and DARPins. From basic research to drug approval.

Current Opinion in Pharmacology
Achille Patrizio Caputi, Pierluigi Navarra

Abstract

This Pharmacological Perspective describes the pathway that, starting from the deep understanding of ankyrins - a family of proteins with high variability-binding and high specificity-binding characteristics - led to the development of a new class of recombinant-binding proteins, the DARPins (designed ankyrin repeat proteins). These are envisaged as alternatives to mAbs and related biologics, with the potential to overcome certain shortcomings of mAbs. DARPins have relatively low molecular weights (14-21kDas) and more favorable PK profiles than mAbs, are stable proteins that can be easily produced in Escherichia coli and can be used in their monovalent form or conjugated to other moieties, for example, polyethylene glycol (PEG) to enhance their half-life. DARPins can also be engineered to produce bi-specific or tri-specific compounds that bind different epitopes of the same target or two different targets. Abicipar, a first-in-class anti-VEGF-A DARPin had similar efficacy compared to anti-VEGF biologics (bevacizumab, ranibizumab) in preclinical studies and was not inferior to ranibizumab in the treatment of age-related macular degeneration (AMD) with a reduced number of intravitreal injections. Abicipar has recently been submit...Continue Reading

References

Jan 1, 1982·Journal of Cellular Biochemistry·V Bennett
Nov 29, 2002·The EMBO Journal·Peter MichaelyRichard G W Anderson
Dec 31, 2004·The New England Journal of Medicine·Evangelos S GragoudasUNKNOWN VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group
Apr 27, 2005·The Journal of Biological Chemistry·Patrick AmstutzAndreas Plückthun
Mar 23, 2006·Protein Engineering, Design & Selection : PEDS·Patrick AmstutzAndreas Plückthun
Oct 6, 2006·The New England Journal of Medicine·Philip J RosenfeldUNKNOWN MARINA Study Group
Oct 6, 2006·The New England Journal of Medicine·David M BrownUNKNOWN ANCHOR Study Group
Jul 16, 2008·Drug Discovery Today·Michael T StumppPatrick Amstutz
Aug 19, 2008·Journal of Molecular Biology·Daniel SteinerAndreas Plückthun
Jan 13, 2010·Journal of Drug Targeting·William M Pardridge
Apr 30, 2011·The New England Journal of Medicine·UNKNOWN CATT Research GroupGlenn J Jaffe
Oct 23, 2012·Ophthalmology·Jeffrey S HeierUNKNOWN VIEW 1 and VIEW 2 Study Groups
Jan 28, 2014·Ophthalmology·UNKNOWN Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group
Jan 7, 2015·Annual Review of Pharmacology and Toxicology·Andreas Plückthun
Mar 31, 2015·Current Opinion in Ophthalmology·Paula E Pecen, Peter K Kaiser
Apr 8, 2015·Ophthalmology·Jennifer J ArnoldUNKNOWN Fight Retinal Blindness Study Group
Nov 10, 2018·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·David CallananSusan Schneider
Feb 16, 2019·Ophthalmic Surgery, Lasers & Imaging Retina·Derek KunimotoUNKNOWN BAMBOO and CYPRESS Study Groups
Sep 21, 2019·Eye·Elad Moisseiev, Anat Loewenstein
Oct 2, 2019·Eye·Ashish SharmaFrancesco Bandello
Feb 27, 2020·The Journal of Pharmacology and Experimental Therapeutics·Kenneth T LuuMayssa Attar

❮ Previous
Next ❯

Citations

Nov 7, 2020·International Journal of Molecular Sciences·Federico RicciMarco Zarbin
Jun 23, 2021·Nature Communications·Georgios N HatzopoulosPierre Gönczy
Aug 28, 2021·International Journal of Pharmaceutics·Huanbo TanPeijian Zou
Sep 8, 2021·Cancer Cell International·Reza MahmoudiMohammad Rahmati

❮ Previous
Next ❯

Related Concepts

Related Feeds